Latest filing published 16 Jun 2025 for Tarsus Pharmaceuticals, Inc..
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +159.9%Entry US$20.01 · Close at T+365 US$52.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Andrew D. Goldberg: trading record in brief
Andrew D. Goldberg is a declared insider of Tarsus Pharmaceuticals, Inc., with filings sourced from SEC (Form 4). In total, 5 filings cover trades dated from 16 June 2023 to 13 June 2025.
Every open-market trade on record is a purchase: 1 purchase worth €17k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 4 option exercises.
The latest filing, published on 16 June 2025, reports an option exercise in Tarsus Pharmaceuticals, Inc. The most recent open-market purchase was published on 19 December 2023, 1,055 days ago. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Andrew D. Goldberg
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 3,350 sharesCommon StockSEC:0001819790-25-000092:0
- 7,000 shares@ US$12.8982.9% of flowCommon StockSEC:0001819790-25-000030:0
- 3,350 sharesCommon StockSEC:0001819790-24-000103:0
- 1,000 shares@ US$18.9617.1% of flowCommon StockSEC:0001827722-23-000002:0Canonical exit: 14 Mar 2024 (T+90)
- 2,000 sharesCommon StockSEC:0001819790-23-000043:0
5 of 5 declarations
